Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis

Enter characteristics of your patient with myelodysplastic syndrome (MDS) into this online tool to receive treatment recommendations from 5 experts.

Rami S. Komrokji, MD
Program Director Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Michael J. Savona, MD Amer Zeidan, MBBS, MPH Released: May 9, 2022

Experts answer HCP questions on myeloproliferative neoplasms (MPNs), from Clinical Care Options (CCO)

Prithviraj Bose, MD
Program Director Stephen Oh, MD, PhD Brady L. Stein, MD, MHS Released: May 3, 2022

Video from Clinical Care Options (CCO): Drs. Prithviraj Bose, Stephen Oh, and Brady Stein discuss key data on myeloproliferative neoplasms

Prithviraj Bose, MD Stephen Oh, MD, PhD Brady L. Stein, MD, MHS Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: April 21, 2022 Expired: April 20, 2023

Gain clinical insights quickly with this short slideset from Clinical Care Options (CCO) on treating patients with myeloproliferative neoplasms (MPNs)

Prithviraj Bose, MD Stephen Oh, MD, PhD Brady L. Stein, MD, MHS Released: March 2, 2022